Galanin and its receptors (GAL1, GAL2, GAL3) modulate a range of neuronal, immune and vascular activities. In vivo administration of
SNAP 37889 (1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1H-indol-2-one), a potent small non-peptidergic antagonist of GAL3, was reported to reduce anxiety- and depression-related behavior,
ethanol consumption, and antagonizes the effect of
galanin on plasma extravasation in rodent models. Accordingly,
SNAP 37889 has been proposed as a potential therapeutic agent to treat anxiety and depression disorders. Therefore, we evaluated the toxicity of
SNAP 37889 to different cell types. Our experiments revealed that
SNAP 37889 (≥10μM) induced apoptosis in epithelial (HMCB) and microglial (BV-2) cell lines expressing endogenous GAL3, in peripheral blood mononuclear cells and promyelocytic
leukemia cells (HL-60) expressing GAL2, and in a neuronal cell line (SH-SY5Y) lacking
galanin receptor expression altogether. In conclusion,
SNAP 37889 is toxic to a variety of cell types independent of GAL3 expression. We caution that the clinical use of
SNAP 37889 at doses that might be used to treat anxiety- or depression- related diseases could have unexpected non-
galanin receptor-mediated toxicity, especially on immune cells.